273 results about "Pulmonary disorders" patented technology

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention discloses an application of phenyllactic acid or a composition containing phenyllactic acid in preparation of medicines for relieving lung diseases, and in the application, the lung diseases are preferably pulmonary fibrosis or acute lung injury. In an acute lung injury research model, phenyllactic acid can effectively intervene in the inflammatory factor cascade reaction and oxidative stress injury process, and acute lung injury symptoms caused by the factors are remarkably improved. Compared with the traditional treatment means, the experiment proves that the phenyllactic acid or the composition containing the phenyllactic acid can obviously relieve the symptoms of acute lung injury (ALI) of mice induced by lipopolysaccharide (LPS) and pulmonary fibrosis (PF) of mice induced by bleomycin, the pathological change of the lung is effectively improved, and the lung function is recovered.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The present invention relates to a pharmaceutical composition in inhalable pre-metered dry powder form that comprises at least one excipient (for example carrier) and at least one active substance used against viral diseases to locally administer it to the lungs for use in the treatment of symptoms of viral lung diseases including COVID-19 caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-COV-2) by means of dry powder inhaler through inhalation. The present invention also relates to methods for preparation of said pharmaceutical composition and the use of these active substances in symptoms caused by COVID-19. similar viral lung diseases, influenza.

The invention provides an application of a polypeptide Nod-T3 in preparation of a medicine for treating lung diseases, the polypeptide Nod-T3 is derived from human protein, has the effect of remarkably inhibiting chronic lung inflammation and fibrosis caused by smoking, can be used for treating COPD and other smoking-related lung diseases, and is high in biocompatibility, small in toxicity, low in cost and suitable for clinical application. The polypeptide has the potential and development value of becoming a novel polypeptide drug.

Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4 / 5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.

The invention provides a multi-element machine learning model-based cross-species lung disease characteristic gene screening method and system, an electronic system and a storage device. The method comprises the following steps of: acquiring single cell / transcriptome data related to mouse lung diseases from a public database and preprocessing the single cell / transcriptome data; training the model by adopting six machine learning algorithms and outputting a gene importance score; calculating the weight according to the model performance and normalizing the score; and integrating the cross-species scores through a weighted fusion formula, and outputting a feature gene list and a visual report. The system comprises a data acquisition and preprocessing module, a multi-element machine learning model training module, a weight calculation and normalization module, a cross-species comprehensive scoring module and a result output module. The screening accuracy, stability and generalization ability are improved through multi-algorithm integration and cross-species fusion, and the method can be widely applied to the fields of mechanism research of lung diseases, diagnosis marker development and drug target verification.

This therapeutic drug for acute pulmonary disorder comprises, as an active ingredient, extracellular vesicles derived from airway epithelial cells.

The invention relates to the technical field of medical equipment, in particular to a spray dosing device and system for lung diseases, comprising a shell in which a medicine storage bin for storing liquid medicine and an atomizing component for atomizing and spraying the liquid medicine are mounted, the atomization assembly is communicated with the medicine storage bin, the respiration triggering assembly is installed at the end, away from the medicine storage bin, of the atomization assembly, the airflow adjusting assembly is installed in the atomization assembly, and the atomization assembly is communicated with the medicine storage bin. The airflow adjusting assembly is in signal connection with a controller, and the controller is in signal connection with the atomization assembly and the respiration triggering assembly. The system is used for achieving accurate and intelligent spray administration according to the breathing state of a patient, the deposition efficiency of medicine in the lung is improved, the treatment effect is optimized, and formulation of a personalized treatment scheme is achieved.

The invention discloses a method and a system for extracting a region of interest of a lung disease pathology full-slice image, relates to extraction of a region of interest, and aims to solve the technical problem of low accuracy of region of interest extraction in the prior art. Comprising the following steps: acquiring lung image data and calculating a semantic similarity score and a visual representation vector of each block; obtaining an optimal threshold according to the semantic similarity score, and screening out an index set; clustering the visual representation vectors of the blocks in the index set, and selecting the block with the highest semantic similarity score in each cluster as a representative block to obtain the index set; and based on the index set, extracting a feature matrix of each representative block, and backtracking to a space coordinate position of each representative block in the corresponding lung image data through an index to obtain a region of interest. Self-adaptive threshold filtering and recognition are carried out according to the semantic similarity score, and heterogeneity distribution of different wettability characteristics in the slice is reserved in the selected region of interest.

The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, the bacterium H. pylori in a subjects digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.

The invention relates to the technical field of cell biology, in particular to application of a composition containing a mesenchymal stem cell secretor in pulmonary fibrosis. A systematic pharmacodynamic experiment verifies that the composition can remarkably reduce the content of a key fibrosis promoting factor TGF-beta1 in the blood of a pulmonary fibrosis model rat and effectively improve the blood-gas exchange function at the same time, and the blood oxygen saturation (SaO2) is remarkably increased, and the partial pressure of carbon dioxide (pCO2) is remarkably reduced. The improvement of the key indexes proves that the composition has a definite anti-fibrosis effect and a lung function protection effect, and a brand new treatment strategy is provided for pulmonary fibrosis diseases which lack special-effect treatment clinically at present. The technology not only has a remarkable clinical transformation value, but also develops an innovative research thought for the lung disease treatment field based on the action mechanism of the stem cell secretor, and has important scientific significance and market development prospect.

Disclosed herein are double stranded ribonucleic acids (dsRNAs) and synthetic antisense oligonucleotides (ASOs) for use in inhibiting the expression of MUC5B and in the treatment of a subject having a disease or disorder characterized by overexpression of MUC5B, including in subjects having lung disease or in a subject at risk of developing lung disease, for example, in a subject having or at risk of developing idiopathic pulmonary fibrosis.

Provided are methods and systems for measuring lung function, such as shunt and deadspace, using pulmonary gas exchange in management and treatment of pulmonary diseases including COVID-19.

The application belongs to the field of digital medicine, and particularly relates to a chronic obstructive pulmonary disease (COPD) differential system based on digital lung sound, a construction method and application thereof. The system comprises a data acquisition module, a preprocessing module, a conversion module, a data module, a data processing module, a data enhancement training module, a deep learning module, a differential module, a grading module and a display module. Digital lung sound records of candidates are collected, converted into mel spectrograms, and diagnosed by using a deep neural network. The candidates are COPD patients, healthy people, or people suffering from other lung diseases, and the disease grade of the COPD patients is given by a device carrying the differential system. The examination only needs to collect lung sounds in clinical or other places, reduces radiation damage and possible infection risk in the conventional diagnosis process, and provides a scheme for early diagnosis of COPD, and improves the diagnosis efficiency of the respiratory department, especially the COPD disease.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

The invention relates to an infectious lung disease standard database establishment method, which comprises the following steps that various types of data sources associated with infectious lung diseases of different sample users are acquired, and the data sources comprise clinical data, iconography data, etiology data and genetics and molecular data; performing data standardization processing on the data source to obtain a standardized data source; performing data cleaning and preprocessing on the standardized data source to obtain preprocessed data; performing data annotation and annotation on the preprocessed data to obtain annotated data; and pre-determining a database management system and a data privacy rule which needs to be followed, processing the labeled data through the data privacy rule, and performing data storage based on the pre-determined database management system to form an infectious lung disease standard database. According to the method, an infectious lung disease standard database is established, so that medical research and clinical practice are promoted, and formulation of public health policies and optimization of disease prevention and control are promoted.

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

Disclosed herein are methods, compounds, and compositions for treating or preventing an inflammasome-mediated disease or condition, including an inflammasome-mediated pulmonary disease or condition.

The present disclosure relates to the detection of acute respiratory distress syndrome in a patient. Subjects of the present disclosure are a computer system, a method and a computer program product for detection of acute respiratory distress syndrome.

The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV capsid protein and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.

The application discloses CpG-containing oligodeoxynucleotide (ODN) with the function of regulating the body's immune capacity and application thereof. The oligodeoxynucleotide in the application is different from the design concept of traditional A-type CpG ODN in sequence and structure, embodies the complex drug-making rule and overcomes the problem of traditional A-type CPG in drug-making. The oligodeoxynucleotide has excellent activity of regulating the body's immune function in vitro and in vivo, can stimulate the production of I, II and III type interferons, regulates the Th1 type immune response, and inhibits the Th2 type and Th17 type inflammatory response. Therefore, the oligodeoxynucleotide can prevent and treat allergic diseases caused by Th2 type immune response, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophil and Th17 related diseases, can prevent and treat the infection and spread of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites, can improve the immune level of the elderly and immunodeficient population, can convert "cold tumor" into "hot tumor", improve the effect of cancer immunotherapy, can prevent and treat central nervous system diseases related to immune dysfunction such as Alzheimer's disease, and can be applied to other diseases related to immune dysfunction.

Provided is a pharmaceutical for lung regeneration, the pharmaceutical containing vascular endothelial stem cells. Also provided is a method for producing an alveolar organoid, the method comprising a step for three-dimensional co-culture of vascular endothelial stem cells and alveolar epithelial cells. This pharmaceutical for lung regeneration is useful in the treatment of lung disease accompanied by alveolar damage, such as chronic obstructive lung diseases, infectious lung diseases, and pulmonary fibrosis.

The present disclosure relates to a pharmaceutical composition comprising an inhalable immunosuppressive macrocyclic active ingredient for use in the prevention or treatment of a pulmonary disease or condition in a subject, wherein the pharmaceutical composition is administered to the subject by inhalation in the form of an aerosol, and wherein the aerosol is produced by nebulizing the pharmaceutical composition using a nebulizer (100), which nebulizer comprises: a) an aerosol generator (101) comprising: - a fluid reservoir (103) for holding the pharmaceutical composition or an interface configured to connect a fluid reservoir, and a vibrating membrane (110) with a plurality of apertures, which apertures are adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of up to about 4.0 gm as measured with aqueous 0,9% (w / v) sodium chloride solution; b) a chamber (105) for temporarily receiving the aerosol produced by the aerosol generator (101), wherein the chamber has an internal lumen with a volume in the range of about 50 to about 150 ml; and c) a mouthpiece (40) for delivering the aerosol provided by the nebulizer (100) to the subject, wherein the mouthpiece has an exhalation filter (30).,

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.

The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the treatment of rare chronic inflammatory pulmonary diseases. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes.

Modulators of extracellular signal-regulated kinase, pharmaceutical compositions thereof, and uses of the compound and pharmaceutical compositions thereof for treating cancer and pulmonary diseases are disclosed.

The application discloses a kind of X-ray film lung disease screening systems of fusing multi-level features, including lung parenchyma segmentation module, lung disease preliminary screening module, multi-level feature construction module, lung disease screening module;Lung parenchyma segmentation module is used to obtain lung parenchyma part from complete chest X-ray film segmentation;Lung disease preliminary screening module is used to construct based on feature consistency variation auto-encoding generation adversarial network and train it, and obtains preliminary screening abnormal score using trained generation adversarial network;Multi-level feature construction module is used to extract features of different semantic levels, including the extraction of bottom visual features, middle layer depth features and high layer experience features;Lung disease screening module is used to construct lung disease screening model using multi-level features and the abnormal score obtained by lung disease preliminary screening module, and obtains the final lung disease classification result.The present application can effectively solve the problem that current computer-aided lung disease screening field research is difficult to be applied to practical clinical scene.

The present invention is based on the surprising discovery that a lipid nanoparticle (LNP) bearing sialic acid residues on the surface can withstand nebulization and maintain its integrity. The invention provides an LNP composition comprising a lipid bearing, or substituted by, a sialic acid (SA) residue such as a ganglioside, a ganglioside derivative, a mimetic, a SA-bearing entity or a combination thereof. The lipid nanoparticles described herein can incorporate nucleic acid molecules, or cargos, withstanding nebulization, and delivering the cargos to the lung via a nebulization-mediated delivery. The present invention also provides methods of using the LNP compositions described herein for pharmaceutical applications. For example, the LNPs provided herein are useful for the treatment of various pulmonary diseases. The LNPs provided herein are also useful for prophylactic applications including vaccines for infectious diseases, allergies, autoimmune diseases and cancer.